Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402 - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

233

Citations

26

References

2008

Year

Akira Inoue, Shunichi Sugawara, Koichi Yamazaki, Makoto Maemondo, Toshiro Suzuki, Kazunori Gomi, Shingo Takanashi, Chieko Inoue, Minoru Inage, Hiroshi Yokouchi,

Journal of Clinical Oncology

Abstract

Amrubicin may be superior to topotecan with acceptable toxicity for previously treated patients with SCLC. Further evaluation of amrubicin for relapsed SCLC is warranted.

References

	Year	Citations
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, Journal of Clinical Oncology	2006	1.8K
Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd, Journal of Clinical Oncology	1999	943
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Andrea Ardizzoni, H. Hansen, P Dombernowsky, Journal of Clinical Oncology	1997	479
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. N Masuda, M. Fukuoka, Y Kusunoki, Journal of Clinical Oncology	1992	448
Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol, Journal of Clinical Oncology	2007	380
Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301 Sayaka Onoda, Noriyuki Masuda, Takashi Seto, Journal of Clinical Oncology	2006	226
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Joan H. Schiller, K Kim, Paul R. Hutson, Journal of Clinical Oncology	1996	210
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer Eelco Fokkema, Bonne Biesma, Wolfgang Snoek, British Journal of Cancer OncologyMedicinePathologyPhase Ii StudyBronchial Neoplasm	1998	182
Activity of docetaxel (Taxotere) in small cell lung cancer J F Smyth, I E Smith, C. Sessa, European Journal of Cancer MedicinePharmacologyAnti-cancer AgentOncologyLung Cancer	1994	138
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Román Pérez-Soler, Bonnie S. Glisson, John Lee, Journal of Clinical Oncology	1996	131

Page 1